1. (((1r)-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic Acid, 1-methylethyl Ester
2. Al 6221
3. Al-6221
4. Al6221
5. Travatan
6. Travatan Z
7. Z, Travatan
1. 157283-68-6
2. Travatan
3. Travatan Z
4. Izba
5. Al-6221
6. Travaprost
7. Trovoprost
8. Otx-tp
9. Chebi:746859
10. Propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
11. Al6221
12. Wj68r08kx9
13. Nsc-760366
14. Travoprost [usan]
15. Travatanz
16. (z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r,e)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
17. Isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
18. Travatan (tn)
19. 5-heptenoic Acid, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-, 1-methylethyl Ester, (5z)-
20. Propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
21. Propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
22. Travoprostum
23. Unii-wj68r08kx9
24. (((1r)-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic Acid, 1-methylethyl Ester
25. (+)-fluprostenol Isopropyl Ester
26. Travoprost [usan:usp:inn:ban]
27. Travoprost In Bulk
28. Travoprostintermediates
29. Travoprost [mi]
30. Travoprost [inn]
31. Travoprost [jan]
32. Travoprost [vandf]
33. Travoprost [mart.]
34. Travoprost [usp-rs]
35. Travoprost [who-dd]
36. Schembl93818
37. Travoprost (jan/usp/inn)
38. (1r-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic Acid, 1-methylethyl Ester
39. (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
40. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester, (1r-(1alpha(z),2beta(1e,3r*),3alpha,5alpha))-
41. Travoprost [ema Epar]
42. Gtpl7102
43. Chembl1200799
44. Travoprost [orange Book]
45. Dtxsid80896948
46. Travoprost [usp Monograph]
47. Duotrav Component Travoprost
48. Ex-a1772
49. Hy-b0584
50. Zinc4474682
51. Bdbm50248302
52. S3738
53. Akos024458039
54. Travoprost Component Of Duotrav
55. Ac-6103
56. Am84515
57. Ccg-269692
58. Db00287
59. Nsc 760366
60. Ncgc00346741-02
61. 5-heptenoic Acid, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester, (5z)-
62. Bs-15509
63. Fluprostenol Isopropyl Ester;al6221;flu-ipr
64. D01964
65. 283t686
66. Sr-01000942266
67. Sr-01000946860
68. J-502633
69. Q2193376
70. Sr-01000942266-1
71. Sr-01000946860-1
72. Fluprostenol Isopropyl Ester, >=98%, Ethanol Solution
73. (1r-(1.alpha.(z),2.beta.(1e,3r*),3.alpha.,5.alpha.))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic Acid, 1-methylethyl Ester
74. (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic Acid 1-methyethyl Ester
75. (z)-isopropyl 7-((1r,2r)-3,5-dihydroxy-2-((s,e)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
76. (z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r,e)-3-hydroxy-4-(3-(trifluoromethyl) Phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
77. (z)-isopropyl7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r,e)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoate
78. Isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3r)-3-hydroxy-4-((.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
79. Isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r,e)-3-hydroxy-4-(3-(trifluoromethyl)-phenoxy)-but-1-enyl)-cyclopentyl)-hept-5-enoate
| Molecular Weight | 500.5 g/mol |
|---|---|
| Molecular Formula | C26H35F3O6 |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 13 |
| Exact Mass | 500.23857332 g/mol |
| Monoisotopic Mass | 500.23857332 g/mol |
| Topological Polar Surface Area | 96.2 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 693 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Travatan z |
| PubMed Health | Travoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Travoprost is a synthetic prostaglandin F analogue. Its chemical name is [1R-[1(Z),2(1E,3R*),3,5]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular f... |
| Active Ingredient | Travoprost |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.004% |
| Market Status | Prescription |
| Company | Alcon Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Travoprost |
| PubMed Health | Travoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Travoprost is a synthetic prostaglandin F analogue. Its chemical name is [1R-[1(Z),2(1E,3R*),3,5]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular f... |
| Active Ingredient | Travoprost |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; ophthalmic |
| Strength | 0.004% |
| Market Status | Tentative Approval; Prescription |
| Company | Par Pharm |
| 3 of 4 | |
|---|---|
| Drug Name | Travatan z |
| PubMed Health | Travoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Travoprost is a synthetic prostaglandin F analogue. Its chemical name is [1R-[1(Z),2(1E,3R*),3,5]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular f... |
| Active Ingredient | Travoprost |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.004% |
| Market Status | Prescription |
| Company | Alcon Pharms |
| 4 of 4 | |
|---|---|
| Drug Name | Travoprost |
| PubMed Health | Travoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Travoprost is a synthetic prostaglandin F analogue. Its chemical name is [1R-[1(Z),2(1E,3R*),3,5]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular f... |
| Active Ingredient | Travoprost |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; ophthalmic |
| Strength | 0.004% |
| Market Status | Tentative Approval; Prescription |
| Company | Par Pharm |
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.
FDA Label
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5. 1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5. 1).
Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5. 1).
Treatment of glaucoma
Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analog that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoprost free acid is potent and highly selective for the FP prostanoid receptor.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
S01EE04
S01EE04
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EE - Prostaglandin analogues
S01EE04 - Travoprost
Absorption
Travoprost is systemically absorbed through the cornea. In humans, peak plasma concentrations of travoprost free acid were low (25 pg/mL or less) and occurred within 30 minutes following topical ocular administration of one drop of 0.004% travoprost ophthalmic solution.
Route of Elimination
Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid. Moreover, elimination from plasma is rapid, resulting in concentrations below the limit of quantitation (< 10 pg/mL) by one hour. Furthermore, in rats, 95% of a subcutaneous radiolabeled dose was eliminated within 24 hours. The major route of elimination was via the bile (61%) with the remainder excreted by the kidneys.
Volume of Distribution
Given the data currently available, it has been recorded that travoprost free acid is moderately distributed into body tissues with a volume of distribution of 2.6 L/kg in rats.
Clearance
Data regarding the clearance of travoprost is not readily available or accessible.
Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is rapidly and extensively metabolized in the kidney, liver, and lung to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.
The terminal elimination half-life of travoprost free acid is determined to be approximately 45 minutes, although studies demonstrated half-life values that ranged from 17 to 86 minutes.
Travoprost, a prostaglandin F2 analogue, is a highly selective full agonist which has a high affinity for the prostaglandin FP receptor, and facilitates reductions in intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways. Reduction of the intraocular pressure in man starts about 2 hours after administration and maximum effect is reached after 12 hours. Significant lowering of intraocular pressure can be maintained for periods exceeding 24 hours with a single dose.
LOOKING FOR A SUPPLIER?
